Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback

Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Longtime biotech investor Les Funtleyder joins us to explain why the recent interest rate hike is bad for biotech and just what it will take for the industry to get out of its slump. Then, vaccinologist and FDA adviser Paul Offit calls in to talk about the impending authorization of Covid-19 vaccines for young children and what it means for the future of the pandemic. We also explain the latest disappointing clinical trial in Alzheimer’s disease and some perplexing data on Pfizer’s Covid-19 antiviral.

For more on what we cover, here’s more on the FDA’s vaccine deliberations; here’s the news in Alzheimer’s; here’s the story on Paxlovid; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].